Ovarian cancer vaccine - Onyvax/Mayo Clinic

Drug Profile

Ovarian cancer vaccine - Onyvax/Mayo Clinic

Alternative Names: Onyvax-O; OnyvaxO

Latest Information Update: 01 Jun 2010

Price : $50

At a glance

  • Originator Mayo Clinic; Onyvax
  • Developer Onyvax
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ovarian cancer

Most Recent Events

  • 10 Dec 2007 Preclinical development is ongoing
  • 15 Jan 2004 Preclinical trials in Ovarian cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top